DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/893d6q/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Ischemia Reperfusion Injury Overview
- Therapeutics Development
- Pipeline Products for Ischemia Reperfusion Injury - Overview
- Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis
- Ischemia Reperfusion Injury - Therapeutics under Development by Companies
- Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes
- Ischemia Reperfusion Injury - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ischemia Reperfusion Injury - Products under Development by Companies
- Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes
- Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
- Alligator Bioscience AB
- Angion Biomedica Corp.
- Antipodean Pharmaceuticals, Inc.
- Biomedica Management Corporation
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Enteris BioPharma, Inc.
- Erimos Pharmaceuticals, LLC
- Gilead Sciences, Inc.
- Kowa Company, Ltd.
- LG Life Science LTD.
- Omeros Corporation
- Opsona Therapeutics Limited
- Peptinnovate Limited
- Pharming Group N.V.
- PledPharma AB
- Prolong Pharmaceuticals
- Proteo, Inc. (Inactive)
- Prothix BV
- Trophos SA
- Zealand Pharma A/S
For more information visit http://www.researchandmarkets.com/research/893d6q/ischemia